Dr. Iraklis Agiovlasitis

National Documentation Centre (EKT/NHRF)

National Contact Point ICT & FET

Horizon 2020:

Funding for academic & business

research partnerships

19-21 May 2014 | PSMR 2014

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

What is Horizon 2020

• Commission proposal for a 80 billion euro research

and innovation funding programme (2014-2020)

• A core part of Europe 2020, Innovation Union &

European Research Area:

› Responding to the economic crisis to invest in future jobs and growth

› Addressing people’s concerns about their livelihoods, safety and

environment

› Strengthening the EU’s global position in research, innovation and

technology

Impact of R&D on economic recovery

BE

BG

CZ

DK

DE

EE

IE

EL

ES

FR

IT

CYLV LT

LU

HU

NL

AT

PL

PT

ROSK

FI SE

UK

0,0

0,5

1,0

1,5

2,0

2,5

3,0

3,5

4,0

-5,0 -4,0 -3,0 -2,0 -1,0 0,0 1,0 2,0 3,0 4,0 5,0 6,0

Avera

ge R

&D

in

vestm

en

t, 2

004

-2009

GDP growth, 2010

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

1. Excellent science

2. Industrial leadership

3. Societal challenges

7

1. Excellent science

2. Industrial leadership

3. Societal challenges

8

Idea

Production Solution

1. Excellent science

2. Industrial leadership

3. Societal challenges

9

Academia

Academia

+

Industry

Academia

+

Industry

+

End-users

Priority 1 | Excellent science

Why:

• World class science is the

foundation of tomorrow’s

technologies, jobs and

wellbeing

• Europe needs to develop,

attract and retain research

talent

• Researchers need access to

the best infrastructures

Priority 2 | Industrial leadership

Why:

• Europe needs more

innovative SMEs to create

growth and jobs

• Strategic investments in key

technologies (e.g. advanced

manufacturing, micro-

electronics) underpin

innovation across existing and

emerging sectors

• Europe needs to attract more

private investment in

research and innovation

Priority 3 | Societal challenges

Why:

• EU policy objectives (climate,

environment, energy, transport

etc) cannot be achieved without

innovation

• Breakthrough solutions come

from multi-disciplinary

collaborations, including social

sciences & humanities

• Promising solutions need to be

tested, demonstrated and

scaled up

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

Types of actions

Research & Innovation Actions (RIA)

• 100%

• 3 entities minimum

Innovation Actions (IA)

• 70-100%

• 3 entities minimum

Coordination & Support (CSA)

• 100%

• 1 entity minimum

SME Instrument

• 70-100%

• Only SMEs

• 1 entity minimum

Fast track to innovation

• Maximum 5 entities

• > 2015

PCPs/PPPs

• Multi-annual framework partnerships

Research Grants

• ERC

Mobility Grants

• Marie Sklodowska Curie

Research & Innovation Actions (RIA)

• 100%

• 3 entities minimum

Innovation Actions (IA)

• 70-100%

• 3 entities minimum

Coordination & Support (CSA)

• 100%

• 1 entity minimum

SME Instrument

• 70-100%

• Only SMEs

• 1 entity minimum

Fast track to innovation

• Maximum 5 entities

• > 2015

PCPs/PPPs

• Multi-annual framework partnerships

Research Grants

• ERC

Mobility Grants

• Marie Sklodowska Curie

Specific Challenge Collaborative Research Projects Networks

Market-driven

R&D

Bottom-up

Academic grants

Commercial

innovation

Collaborative Research

Specific Challenge

Scope

Impact

Research & Innovation Actions (RIA)

• 100%

• 3 entities minimum

Innovation Actions (IA)

• 70-100%

• 3 entities minimum

Health, Demographic Change & Well-beingSC1

Future & Emerging TechnologiesFET

Information & Communication TechnologiesICT

Nanotechnologies, Materials, Biotechnology, Processing"NMPPersonalising Health Care

Nano-medicine

eHealth

PHC-11-2015: Development of new diagnostic tools and technologies: in vivo

medical imaging technologies

Specific challenge: The development of new diagnostics (more sensitive, robust and selective) for improved clinical

practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical

applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving, and

often complex technologies. Improved clinical decisions based on new and improved diagnostic tools and techniques

should lead to better health outcomes while contributing to the sustainability of the health care system. This is also a field

where many small European companies are active.

Scope: Proposals should focus on the development of innovative in vivo imaging tools and technologies. The novel

application of existing tools and technologies is not included. Tools and technology should aim at improving

diagnosis, prediction, monitoring, image-based intervention or assessment of therapeutic response, with a significant

impact on clinical decisions and health outcomes. Proposals should focus on innovations that offer a clear advantage over

existing tools and technologies. Development of in vivo medical imaging technologies should make use of existing high-

tech engineering or physics solutions or innovative ideas and concepts coming from those fields and if appropriate, new

developments in the field of imaging agents.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would

allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection

of proposals requesting other amounts.

Expected impact: This should provide:

• New in vivo diagnostic tools and methods providing more accurate, less invasive, more reliable and earlier

disease diagnosis, prediction or response to therapy, leading to improved clinical decisions and outcomes.

• Contribution to the sustainability of health care systems.

• Growth of the European diagnostics sector, in particular for SMEs.

Type of action: Research and innovation actions

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2277-phc-11-2015.html

SME Instrument SME Instrument

• 70-100%

• Only SMEs

• 1 entity minimum

Phase 1: Concept and feasibility assessment

Phase 2: R&D, demonstration,

market replication

Input: Idea/Concept: "Business Plan 1"

(~ 10 pages) 10% budget

Activities:Feasibility of concept

Risk assessmentIP regime

Partner searchDesign study

Pilot applicationetc.

Output: elaborated "Business plan 2"

Input: "Business plan 2" plus description of activities under Phase

2 (~ 30 pages)90% budget

Activities:Development,

prototyping, testing, piloting,

miniaturisation, scaling-up, market

replication, research

Output: "investor-ready Business plan 3"

Lump sum: 50.000 €

~ 6 months

Phase 3: Commercialisation

1-5 M€ EC funding

~ 12 to 24 months

Promote instrument as quality label for

successful projects

Facilitate access to private finance

Support via networking , training, information,

addressing i.a. IP management,

knowledge sharing, dissemination

SME window in the EU financial facilities (debt

facility and equity facility)

Possible connection to public procurement

activities

10-15% success~ 50% success

PHC-12-2014/2015: Clinical research for the validation of biomarkers and/or

diagnostic medical devices

Specific challenge: The clinical validation of biomarkers will be increasingly important for the development of new

diagnostics, and this is a research area where many small European companies are active.Improved clinical decisions

should lead to better health outcomes while contributing to the sustainability of the health care system.

Scope: The clinical validation of existing potential biomarkers (not the identification of new ones) is sought. This

validation should provide evidence for: high analytical validity; appropriate sensitivity and specificity; clinical validity/ utility.

Preference will be given to validation of biomarkers with high potential for short term uptake into clinical practice. In

addition, validation of the clinical performance of new diagnostic devices can be supported, either in combination

with the biomarker validation, or against existing standards. Both in vivo and in vitro potential biomarkers are eligible.

Preference will be given to the validation of disease related biomarkers (i.e. diagnostic, susceptibility/risk, monitoring and

prognostic biomarkers)

Expected impact: This should provide:

• Increased clinical availability and exploitation of biomarkers for the benefit of the patient.

• New diagnostic devices.

• Facilitation of entry of improved diagnostics in the clinic and the market.

• Support for the implementation of the Commission proposal for a revised in vitro diagnostic devices regulation

• Enhancing profitability and growth performance of SMEs by combining and transferring new and existing knowledge into innovative,

disruptive and competitive solutions seizing European and global business opportunities.

• Contribution to the sustainability of health care systems.

• Increased likelihood of market uptake and distribution of resulting innovations tackling the abovementioned specific challenge(s) in a

sustainable way.

• Leveraging of private investment in clinical validation as described above, notably leverage of private co-investor and/or follow-up

investments.

Type of action: SME instrument (100% funding)

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2540-phc-12-2014-1.html

Public-Private Partnerships (PPPs):• Through Joint Technology Initiatives or other formal structures (§ 187.)

• Via contractual arrangements, which provide inputs for workprogrammes

• Only when criteria met, e.g. clear commitments from private partners

Public-Public Partnerships (P2Ps):• Through “ERA-Nets” for topping up individual calls/ actions (replacing current

ERA-Net, ERA-Net Plus, Inco-Net, Inno-net)

• Through participation in joint programs between Member States (§ 185.)

• Supporting agendas of Joint Programming Initiatives when in line with Horizon 2020

• Only when criteria met, e.g. financial commitments of participating countries

European Innovation Partnerships• Not funding instruments, but for coordination with broader policies and

programmes

PCPs/PPPs

• Multi-annual framework partnerships

Innovative Medicines Initiative 2 (IMI 2)

www.imi.europa.eu

European & Developing Countries Clinical Trials Partnership (EDCTP2)

www.edctp.org

Active & Assisted Living 2www.aal-europe.eu

European Innovation Partnership on Active & Healthy

Ageing (EIP AHA)https://webgate.ec.europa.eu/eipaha

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

…ETC

EU

Financial

Regulation

SINGLE SET OF RULESfor Horizon 2020

SIMPLIFICATION

Adapted for the whole research and innovation cycle

Covering all research programmes and funding bodies

Aligned to the Financial Regulation, coherent with other new EU Programmes.

Rules for Participation: what’s new? (1)1. A SINGLE SET OF RULES

3. SIMPLE EVALUATION CRITERIA

Excellence - Impact - Implementation

4. NEW FORMS OF FUNDING aimed at innovation: pre-commercial procurement,

inducement prizes, dedicated loan and equity instruments.

2. ONE PROJECT - ONE FUNDING RATE. Maximum of 100% of direct costs (except for actions close to market,

where a 70% maximum will apply)

Indirect eligible costs: a flat rate of 25% of direct eligible costs

5. INTERNATIONAL PARTICIPATION: facilitated but better protecting EU

interests.

Rules for Participation: what’s new? (2)

Lowest possible level of requirements for submission of audit certificates without

undermining sound financial management;

Audit strategy focused on risk and fraud prevention.

7. FEWER, BETTER TARGETED CONTROLS AND AUDITS

Beyond the Rules: further simplified provisions in the Grant Agreement and implementing

procedures to facilitate access to Horizon 2020 (Participant Portal).

8. IMPROVED RULES ON INTELLECTUAL PROPERTY

Balance between legal security and flexibility;

Tailor-made IPR provisions for new forms of funding;

A new emphasis on open access to research publications.

6. SIMPLER RULES FOR GRANTS: broader acceptance of participants

accounting practices for direct costs, flat rate for indirect costs, no time-sheets for

personnel working full time on a project, possibility of output-based grants.

Horizon 2020

Priorities

Types of actions

Rules for participation

Support

I. Horizon 2020

Where do I start?

http://ec.europa.eu/horizon2020

II. Participant Portal

http://ec.europa.eu/research/participants/portal/desktop/en/home.html

Where do I start?

http://ec.europa.eu/research/participants/portal/desktop/en/home.html

Where do I start?

National Contact Points

National Contact Points

http://een.ec.europa.eu/

Enterprise Europe Network

One-stop shop for

European SMEs

Practical help from local organisations

Listening to SMEs

Almost 600 partner organisations in

54 countries

One-stop shop for European SMEs

Since its launch, the Network has:

• Helped 7 000 companies to sign business, technology or

research partnerships

• Brought 90,000 companies to international brokerage

events and company missions

• Answered 375,000 questions on EU issues

• Attracted more than 1 million people to events

I need a business partner in another country…

How do I get European funding?

What does this EU law mean for my business?

How do I find a new market abroad?

How can I sell my innovative ideas and technology?

EC Horizon 2020-SC1 http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-

demographic-change-and-wellbeing

Previous projects:

• CORDIS Advanced Search: http://cordis.europa.eu/search/index.cfm?fuseaction=proj.advSearch

• HEALTHCOMPETENCE:

http://www.healtcompetence.eu/converis/publicweb/area/1353

Health, Demographic Change & Well-beingSupport

Partner Search:• Fit for Health 2.0: http://www.fitforhealth.eu

• Ideal-ist (eHealth): http://www.ideal-ist.eu/

• Εnterprise Europe Network:

http://www.enterprise-hellas.gr/

Info-day on SC1

http://ec.europa.eu/research/health/horizon-2020-health-open-info-

days_en.html

Netwatch – Platform on Τransnational R&D programme Collaboration

http://netwatch.jrc.ec.europa.eu/web/ni/network-information/joint-calls

Health, Demographic Change & Well-beingSupport

Dr. Iraklis Agiovlasitis | agiovlasitis@ekt.gr

National Contact Point ICT & FET Horizon 2020

EKT | National Documentation Centreweb.ekt.gr • www.ekt.gr/horizon2020

Thanks!